Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study assessing iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy

Next Previous
Search
Trial Profile

A retrospective study assessing iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SoliSimplify

    • Most Recent Events

    • 26 Dec 2022 Results comparing the clinical effectiveness of once-daily iGlarLixi versus a multiple-injection BI + rapid acting insulin regimen in adults with T2D published in the Diabetes, Obesity and Metabolism
    • 23 Sep 2022 Primary endpoint (Non-inferiority of iGlarLixi to BI+RAI in HbA1c change from baseline to 6 months) has been met, according to a results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Sep 2022 Results assessing the non-inferiority of iGlarLixi to BI + RAI in HbA1cchange from baseline to 6 months presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top